within Pharmacolibrary.Drugs.ATC.B;

model B01AC21
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.6166666666666667,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.0146,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Treprostinil is a stable, synthetic analog of prostacyclin (PGI2) used primarily for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity. It acts as a vasodilator of pulmonary and systemic arterial vascular beds and inhibits platelet aggregation. It is approved for use in several countries and can be administered intravenously, subcutaneously, orally, or by inhalation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Hall, K, et al., &amp; Feinstein, JA (2019). Subcutaneous and Intravenous Treprostinil Pharmacokinetics in Children With Pulmonary Vascular Disease. <i>Journal of cardiovascular pharmacology</i> 73(6) 383–393. DOI:<a href=&quot;https://doi.org/10.1097/FJC.0000000000000674&quot;>10.1097/FJC.0000000000000674</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31162247/&quot;>https://pubmed.ncbi.nlm.nih.gov/31162247</a></p></li><li><p>Kumar, P, et al., &amp; Nelsen, A (2016). A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration. <i>Clinical pharmacokinetics</i> 55(12) 1495–1505. DOI:<a href=&quot;https://doi.org/10.1007/s40262-016-0409-0&quot;>10.1007/s40262-016-0409-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27286723/&quot;>https://pubmed.ncbi.nlm.nih.gov/27286723</a></p></li><li><p>Perez, VC, et al., &amp; Rahaghi, FF (2024). Escalating Oral Treprostinil Dose With Intravenous Treprostinil Bridging Therapy. <i>Cureus</i> 16(2) e54184–None. DOI:<a href=&quot;https://doi.org/10.7759/cureus.54184&quot;>10.7759/cureus.54184</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38500893/&quot;>https://pubmed.ncbi.nlm.nih.gov/38500893</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AC21;
